VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
ASCO 2026: Direct Kill + Immune Activation — CELMoD Drug Mezigdomide Shows Promise in Breaking Through Multiple Drug-Resistant, High-Risk Myeloma
ASCO 2026: Direct Kill + Immune Activation — CELMoD Drug Mezigdomide Shows Promise in Breaking Through Multiple Drug-Resistant, High-Risk Myeloma
May 29, 2026 20:41 CST Updated 22:03
Share: